2021
DOI: 10.1155/2021/5172131
|View full text |Cite
|
Sign up to set email alerts
|

TIO Associated with Hyperparathyroidism: A Rarity, a Rule, or a Novel HPT-PMT Syndrome—A Case Study with Literature Review

Abstract: Objective. Association of primary hyperparathyroidism (pHPT) with phosphaturic mesenchymal tumors (PMT) is rarely reported. This report entertains the hypothesis of the causal association of HPT with tumor-induced osteomalacia (TIO) and of the existence of HPT-PMT syndrome. Case Presentation. A 49-year-old man presented with fragility rib fractures, generalized bone pain, and muscle weakness worsening over the past 3 years. Initial tests demonstrated hypophosphatemia and high PTH. The diagnosis of pHPT was ent… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 19 publications
0
2
0
Order By: Relevance
“…Both drugs are administered in multiple daily doses, i.e., phosphate at 1–2 g/day and calcitriol at 1–3 mcg/day. Because of their mechanism and due to the underlying disease, patients may develop secondary or tertiary hyperparathyroidism in the long term [ 51 ]. This is presumably due to reduced calcitriol levels, or because of the mechanism by which phosphate supplements intermittently reduce ionized calcium.…”
Section: Medical Treatmentmentioning
confidence: 99%
“…Both drugs are administered in multiple daily doses, i.e., phosphate at 1–2 g/day and calcitriol at 1–3 mcg/day. Because of their mechanism and due to the underlying disease, patients may develop secondary or tertiary hyperparathyroidism in the long term [ 51 ]. This is presumably due to reduced calcitriol levels, or because of the mechanism by which phosphate supplements intermittently reduce ionized calcium.…”
Section: Medical Treatmentmentioning
confidence: 99%
“…Until the tumor is not localized, oral phosphate and calcitriol should be given to aid mineralization in the bone and alleviate patient symptoms, and to increase serum phosphate levels. Phosphate (1–2 g/day) and calcitriol (1–3 mcg/day) are given in multiple daily doses, and, with long-term exposure, patients may develop secondary or tertiary hyperparathyroidism [ 44 ]. The presumed mechanism is likely due to both deficient 1,25(OH) 2 vitamin D production and phosphate supplementation, which lowers ionized calcium, thereby continuously triggering PTH release.…”
Section: Phosphate In Paraneoplastic Endocrine Tumorsmentioning
confidence: 99%